U.S. markets closed

Equillium, Inc. (EQ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.85-0.20 (-3.31%)
At close: 4:00PM EDT
6.10 +0.25 (4.27%)
After hours: 05:40PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.05
Open6.02
Bid5.85 x 800
Ask6.10 x 800
Day's Range5.80 - 6.08
52 Week Range2.53 - 27.05
Volume176,382
Avg. Volume167,963
Market Cap169.886M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients
    Benzinga

    Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients

    Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD). The results were presented at the European Hematology Association 2021 Virtual Congress. All patients in the study (N=20) were evaluated as high-risk aGVHD and achieved complete response (CR) and overall response rates (ORR) at Day 29 of 55% and 70%, respectively. Responses observed were generally rapid – within 15 days – and d

  • Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
    GlobeNewswire

    Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

    Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical advancement of itolizumab in first-line treatment of aGVHD Conference call today at 8:00 am eastern time LA JOLLA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today a

  • Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
    GlobeNewswire

    Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

    Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseasesLA JOLLA, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a poster presented yesterday at the CYTO Virtual Interactive Meeting, highlighting a novel assay to measure target engagement and modulation of CD6 as a pharmacod